



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, September 17, 2025
Minutes approved by the board on Oct. 15, 2025

Web link to the meeting video: <https://youtu.be/euiMktuaQMw>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20250917-PDAB-document-package.pdf>

Call to order: Chair Shelley Bailey called the meeting to order at 8:04 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Vice Chair Amy Burns, Lauri Hoagland, Dan Kennedy, Chris Laman, John Murray

Absent: Dan Hartung

Chair Bailey announced the board would provide American Sign Language during the meeting. View at video minute [00:00:42](#).

Declaration of conflict of interest, meetings with entities or individuals related to board activities, or testifying before the Legislature: John Murray provided a statement. View at video minute [00:01:09](#).

Approval of board minutes: John Murray made a motion to approve the minutes as shown on [Pages 3-5](#) of the agenda materials and Dan Kennedy provided a second. In the vote, two board members abstained because they did not attend the meeting so the motion failed. (Five votes are needed to pass a motion.) Chair Bailey asked staff to put the Sept. 17 minutes on the Oct. 15 agenda for approval next month. View at video minute [00:03:38](#).

MOTION to approve the Aug. 20, 2025, minutes

Board Vote:

Yes: Dan Kennedy, Chris Laman, John Murray, Chair Shelley Bailey

Abstain: Lauri Hoagland, Vice Chair Amy Burns

Absent: Dan Hartung

Motion failed 4-0

PDAB program update: Cortnee Whitlock, PDAB senior policy analyst, provided a program update. View at video minute [00:05:32](#).

General public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Primo Castro, Biotechnology Innovation Organization (BIO), Lorren Sandt, Caring Ambassadors, Jessica McBride, Oregon Coalition for Affordable Prescriptions, Dharia McGrew, PhRMA, Vanessa Lathan, PIC, LuGina Mendez-Harper, Prime Therapeutics, and Derek Flowers, Value of Care Coalition. The board received 12 written comments, which are posted on the [PDAB website](#). View at video minute [00:08:36](#).



Board discussion: volunteered trade secret information: Cortnee Whitlock, senior policy analyst, led the board in this discussion. View the slide presentation on [Pages 6-13](#). View the discussion at video minute [00:32:45](#).

Board discussion: policy recommendations for including in the 2025 annual legislative report: Cortnee Whitlock, senior policy analyst, led the board in this discussion. View the slide presentation on [Pages 14-23](#). View the discussion at video minute [01:02:09](#).

Board review of methodology for drug reviews and scoring rubric and worksheet: Cortnee Whitlock, senior policy analyst, led the board in the discussion about the drug review roadmap and the rubric and worksheet. View the slide presentation on [Pages 24-32](#). View the discussion at video minute [01:33:23](#).

Drug review for Jardiance - Antidiabetics: The board began discussions about drug reviews. View the Jardiance report on [Pages 33-65](#) posted on the PDAB website. View the discussion at video minute [01:47:34](#).

Drug review for Mounjaro – Antidiabetics: The board continued the discussions about drug reviews. View the Mounjaro report on [Pages 66-98](#). View the discussion at video minute [02:07:12](#).

Drug review for Ozempic - Antidiabetics: The board continued the discussions about drug reviews. View the Ozempic report on [Pages 99-136](#) posted on the PDAB website. View the discussion at video minute [02:23:14](#).

Drug review for Rybelsus –Antidiabetics: The board continued the discussions about drug reviews. View the Rybelsus report on [Pages 137-168](#) posted on the PDAB website. View the discussion at video minute [02:46:50](#).

Drug review for Trulicity –Antidiabetics: The board continued the discussions about drug reviews. View the Trulicity report on [Pages 169-201](#) posted on the PDAB website. View the discussion at video minute [02:54:37](#).

Drug review public comment periods: Chair Bailey read the list of letters about specific drugs under review. No one signed up to speak for the drug review public comment period of Sept. 17. See tables below for list of public comments.

Announcements: Chair Bailey announced the next meeting will be Oct. 15, 2025, at 8 a.m.

Adjournment: Chair Bailey adjourned the meeting at 11:30 a.m. with all board members in agreement. View at minute [03:24:08](#).



Table of public comment speakers

Name of speaker	Association to drug under review	Drug	Format	Date	Exhibit website link
Stacie Phan	Boehringer Ingelheim	Jardiance	Letter	5/21/2025	Exhibit A
Dr. Harry Gewanter	Let My Doctors Decide Action Network	Jardiance	Letter	9/15/2025	Exhibit B
Jennifer Hazen	Patient	Jardiance	Letter	9/15/2025	Exhibit C
Suzanna Masartis	Community Liver Alliance	Mounjaro	Letter	5/12/2025	Exhibit D
Cynthia Ransom	Eli Lilly	Mounjaro	Letter	4/25/2025	Exhibit E
Carol Elkins	Retired, patient	Mounjaro	Letter	6/3/25	Exhibit F
Dr. Harry Gewanter	Let My Doctors Decide Action Network	Mounjaro	Letter	9/15/2025	Exhibit G
Mary Anne Cooper	Regence BlueCross BlueShield	Mounjaro	Letter	9/12/2025	Exhibit H
Jennifer Hazen	Patient	Mounjaro	Letter	9/15/2025	Exhibit I
Suzanna Masartis	Community Liver Alliance	Ozempic	Letter	5/12/2025	Exhibit J
Carol Elkins	Retired, patient	Ozempic	Letter	6/18/25	Exhibit K
Dr. Harry Gewanter	Let My Doctors Decide Action Network	Ozempic	Letter	5/15/2025	Exhibit L
Mary Anne Cooper	Regence BlueCross BlueShield	Ozempic	Letter	9/12/2025	Exhibit M
Suzanna Masartis	Community Liver Alliance	Rybelsus	Letter	5/12/2025	Exhibit N
Dr. Harry Gewanter	Let My Doctors Decide Action Network	Rybelsus	Letter	9/15/2025	Exhibit O
Mary Anne Cooper	Regence BlueCross BlueShield	Rybelsus	Letter	9/12/2025	Exhibit P
Suzanna Masartis	Community Liver Alliance	Trulicity	Letter	5/12/2025	Exhibit Q
Cynthia Ransom	Eli Lilly	Trulicity	Letter	4/25/2025	Exhibit R
Dr. Harry Gewanter	Let My Doctors Decide Action Network	Trulicity	Letter	5/15/2025	Exhibit S
Mary Anne Cooper	Regence BlueCross BlueShield	Trulicity	Letter	9/12/2025	Exhibit T